Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6404146 | 0.85 | EPHX2 (0.43) | EPHX2NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL6402461 | 0.82 | PPARA (0.49) | EPHX2NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL6407566 | 0.81 | RAB9A (0.46) | EPHX2NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL27232984 | 0.79 | EPHX2 (0.40) | EPHX2NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL4204403 | 0.79 | EPHX2 (0.57) | EPHX2NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL2123367 | 0.77 | EPHX2 (0.41) | EPHX2NPC1RAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL6402401 | 0.76 | POLB (0.49) | NOTUMNPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL4017999 | 0.76 | IGF1R (0.44) | EPHX2NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL6402627 | 0.75 | EPHX1 (0.51) | EPHX2NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL4009973 | 0.73 | SMN1; SMN2 (0.48) | NPC1RAB9ASMN1; SMN2POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | EPHX2 1438/4885NOTUM 1823/4885NPC1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.